Detect early Parkinsons via oculography
- Trial ID
- NCT04731246
- Official Title
- Video-oculography and Parkinson's Disease: A Prospective Study
- Goal
- Detect early Parkinsons via oculography
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson Disease, Idiopathic
- Interventions
- Video-oculography / Neuropsychological evaluations
Plain-Language Summary
They want to detect subtle eye movement and thinking changes that could help confirm and track idiopathic Parkinson's disease in early to mid stages. The approach uses video-oculography to precisely record saccades, smooth pursuit, and fixation, paired with neuropsychological tests to link eye movement patterns with cognitive signs, and it is observational so it does not change or interact with levodopa or other Parkinson medications. Adults with clinically defined idiopathic Parkinson's, Hoehn and Yahr stage 1 to 3, a recent brain MRI and a DaTSCAN or F‑DOPA showing presynaptic dopaminergic loss, no major cognitive or other significant neurological or psychiatric disorders, French language ability, and a caregiver are eligible. Enrollment is small and focused, about 30 participants, so it is aimed at refining diagnostic markers rather than testing a treatment.
Locations
- Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital, Monaco, Monaco
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Video-oculography / Neuropsychological evaluations. They want to detect subtle eye movement and thinking changes that could help confirm and track idiopathic Parkinson's disease in early to mid stages. The approach uses video-oculography to precisely record saccades, smooth pursuit, and fixation, paired with neuropsychological tests to link eye movement patterns with cognitive signs, and it is observational so it does not change or interact with levodopa or other Parkinson medications. Adults with clinically defined idiopathic Parkinson's, Hoehn and Yahr stage 1 to 3, a recent brain MRI and a DaTSCAN or F‑DOPA showing presynaptic dopaminergic loss, no major cognitive or other significant neurological or psychiatric disorders, French language ability, and a caregiver are eligible. Enrollment is small and focused, about 30 participants, so it is aimed at refining diagnostic markers rather than testing a treatment.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 10 years and 6 months.